DE2548669C2 - Verwendung von Mercaptoessigsäuren bei der Behandlung von Schleimhauterkrankungen der Atemwege - Google Patents
Verwendung von Mercaptoessigsäuren bei der Behandlung von Schleimhauterkrankungen der AtemwegeInfo
- Publication number
- DE2548669C2 DE2548669C2 DE2548669A DE2548669A DE2548669C2 DE 2548669 C2 DE2548669 C2 DE 2548669C2 DE 2548669 A DE2548669 A DE 2548669A DE 2548669 A DE2548669 A DE 2548669A DE 2548669 C2 DE2548669 C2 DE 2548669C2
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- respiratory tract
- compounds
- acetic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 201000010099 disease Diseases 0.000 title claims description 7
- 210000002345 respiratory system Anatomy 0.000 title claims description 7
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims description 23
- 210000004400 mucous membrane Anatomy 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 210000000621 bronchi Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000510 mucolytic effect Effects 0.000 description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- UVZICZIVKIMRNE-UHFFFAOYSA-N thiodiacetic acid Chemical compound OC(=O)CSCC(O)=O UVZICZIVKIMRNE-UHFFFAOYSA-N 0.000 description 4
- LDUNOJQGMQTSIY-UHFFFAOYSA-N 4-(carboxymethylsulfanyl)butanoic acid Chemical compound OC(=O)CCCSCC(O)=O LDUNOJQGMQTSIY-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- MLLYDWHLZFTQBY-UHFFFAOYSA-N 3-(carboxymethylsulfanyl)propanoic acid Chemical compound OC(=O)CCSCC(O)=O MLLYDWHLZFTQBY-UHFFFAOYSA-N 0.000 description 2
- AHXGXXJEEHFHDK-UHFFFAOYSA-N 6-[(6-hydroxynaphthalen-2-yl)disulfanyl]naphthalen-2-ol Chemical compound C1=C(O)C=CC2=CC(SSC3=CC4=CC=C(C=C4C=C3)O)=CC=C21 AHXGXXJEEHFHDK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salt Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7437397A FR2290894A1 (fr) | 1974-11-13 | 1974-11-13 | Compositions pharmaceutiques contenant des derives de l'acide mercapto-acetique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2548669A1 DE2548669A1 (de) | 1976-06-16 |
| DE2548669C2 true DE2548669C2 (de) | 1984-09-20 |
Family
ID=9144880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2548669A Expired DE2548669C2 (de) | 1974-11-13 | 1975-10-30 | Verwendung von Mercaptoessigsäuren bei der Behandlung von Schleimhauterkrankungen der Atemwege |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE835498A (index.php) |
| DE (1) | DE2548669C2 (index.php) |
| FR (1) | FR2290894A1 (index.php) |
| GB (1) | GB1511179A (index.php) |
| ZA (1) | ZA756921B (index.php) |
-
1974
- 1974-11-13 FR FR7437397A patent/FR2290894A1/fr active Granted
-
1975
- 1975-10-30 DE DE2548669A patent/DE2548669C2/de not_active Expired
- 1975-11-04 ZA ZA00756921A patent/ZA756921B/xx unknown
- 1975-11-07 GB GB46237/75A patent/GB1511179A/en not_active Expired
- 1975-11-12 BE BE161801A patent/BE835498A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BE835498A (fr) | 1976-05-12 |
| FR2290894A1 (fr) | 1976-06-11 |
| ZA756921B (en) | 1976-09-29 |
| GB1511179A (en) | 1978-05-17 |
| FR2290894B1 (index.php) | 1982-02-12 |
| DE2548669A1 (de) | 1976-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3875285T2 (de) | Verwendung von salzen der n-acetylneuraminsaeure zur herstellung eines arzneimittels zum abschwellen der nasenschleimhaut. | |
| EP2214658B2 (de) | Osmolythaltige zubereitung zur anwendung bei trockenen schleimhäuten | |
| WO2008148572A1 (de) | Antiinflammatorische wirkstoffkombinationen zur behandlung von erkrankungen der haut und schleimhäute | |
| EP0501205A1 (de) | Antiphlogistisches Mittel | |
| DE69825279T2 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| DE69111974T2 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
| DE202008012494U1 (de) | Pharmazeutische Zusammensetzung für die nasale Applikation | |
| EP0369216B1 (de) | Arzneimittelzubereitung aus Esterderivaten des Hecogenins und dessen Verwendung zur Behandlung von benigner Prostatahyperplasie | |
| EP0670163A1 (de) | Verwendung von Pentoxifyllin zur Herstellung pharmazeutischer Zubereitungen für die Behandlung granulomatöser und fibrosierender Lungenerkrankungen | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE3142893A1 (de) | Neues substitutionsprodukt von glycin, verfahren zu seiner hertellung und damit gebildete pharmazeutische praeparate | |
| DE2850509C3 (de) | O-Methoxyzimtaldehyd bei der Bekämpfung von Dermatophyten | |
| EP0501206B1 (de) | Phenonverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE2548669C2 (de) | Verwendung von Mercaptoessigsäuren bei der Behandlung von Schleimhauterkrankungen der Atemwege | |
| DE3431727A1 (de) | Nasenspray gegen schnupfen und grippe mit einem gehalt an zinkglukonat | |
| DE4438589A1 (de) | Nasentherapeutikum | |
| DE2028880A1 (en) | N-phenyl carbamoyl derivs of 3-beta-phenyl isopropyl-synononimines - - as psycho and cns | |
| EP3407890B1 (de) | Pharmazeutische zubereitung und deren verwendung in der behandlung von viraler laryngitis | |
| DE3027056A1 (de) | Pharmazeutischer ansatz zur verwendung als schutz gegen akutes lungenoedem, anaphylaktischen schock u.a. arten von schock sowie hyperfibrinolyse | |
| EP2744504B1 (de) | Verfahren zur herstellung von trockenextrakten | |
| EP2591777B1 (de) | L-NIL als Inhibitor zur Regeneration der Lunge von an COPD leidenden Patienten | |
| DE2702535A1 (de) | Neue cysteinderivate, ihre herstellung und verwendung | |
| JP6294773B2 (ja) | 口腔粘膜疾患の予防または治療用経口製剤 | |
| DE2521765A1 (de) | Verwendung von uronsaeuren | |
| DE2205870C2 (de) | Verfahren zur Herstellung der Bisulfitverbindung des 2-Fluorenonylglyoxals und diese Verbindung enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: SYNTHELABO S.A., 75007 PARIS, FR |
|
| 8125 | Change of the main classification |
Ipc: A61K 31/185 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |